Views & Analysis What HCPs say about Roche's breast cancer drug The online conversations about breast cancer drug Kadcyla before it was approved by NICE.
Views & Analysis How healthcare professionals engage NICE online NICE is reaching out and engaging more via social media.
Views & Analysis What doctors say about Obamacare after US election Daniel Ghinn has been listening to the social media conversations of HCPs.
Views & Analysis What doctors say about EpiPen pricing The furore over Mylan’s ‘price gouging’ in relation to EpiPen in the US went global, thanks to social media.
Views & Analysis What doctors say about Theresa May’s reappointment of Jeremy... Reactions of healthcare professionals to Jeremy Hunt staying as Health Secretary.
Views & Analysis What doctors say about the EU referendum Daniel Ghinn tunes into the conversation around the EU referendum, which takes place on Thursday
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
